Synergistic anti-liver cancer effects of curcumin and total ginsenosides

Figure 2 Curcumin and total ginsenosides inhibit the activation of programmed cell death 1/ programmed cell death 1 ligand 1 and Tregs. A subcutaneous liver cancer mouse model was treated with curcumin (Cur), total ginsenosides (TG), or a combination of the two for 21 d, and tumor tissues were harvested as indicated. A-C: The protein levels of programmed cell death 1, programmed cell death 1 ligand 1, Toll like receptor 4, and nuclear factor-κB were evaluated by Western blot analysis. Glyceraldehyde-3-phosphate dehydrogenase was used as the loading control; D: CD4⁺CD25⁺Foxp3⁺ Tregs were evaluated by flow cytometry. Results show the proportion of CD4⁺CD25⁺Foxp3⁺ Tregs in HepG2 subcutaneous tumor tissues of BALB/c mice. Data are presented as the mean ± standard error of the mean, and were compared between two groups using least significant difference or Dunnett’s T3 method. ^aP < 0.05 and ^bP < 0.01 vs vehicle group; ^cP < 0.05 and ^dP < 0.01 vs TG-104 group; ^eP < 0.05 and ^fP < 0.01 vs TG-520 group; ^gP < 0.05 and ^hP < 0.01 vs Cur group; ⁱP < 0.05 and ^jP < 0.01 vs Cur + TG-104 group; ^kP < 0.05 and ^lP < 0.01 vs Cur + TG-520 group. Cur: Curcumin; TG: Total ginsenosides; PD-1: Programmed cell death 1; PD-L1: Programmed cell death 1 ligand 1; Tregs: CD4⁺CD25⁺Foxp3⁺ regulatory T cells; TLR4: Toll like receptor 4; NF-κB: Nuclear factor-κB; DDP: Cisplatin; 5-Fu: 5-fluorouracil.